New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePal-GHK vs Eloralintide

Pal-GHK vs Eloralintide

Side-by-side comparison of key properties, dosing, and research.

Skin & CosmeticAnti-Aging & Longevity
Pal-GHK
GLP-1 / Weight Loss Agonists
Eloralintide
Summary
Pal-GHK is the palmitoylated form of the GHK tripeptide without a copper ion. By conjugating palmitic acid to glycine-histidine-lysine, skin penetration is substantially enhanced, enabling deeper dermal collagen stimulation. It is commonly paired with Pal-GHK-Cu or GHK-Cu in anti-aging formulations.
Eloralintide is a long-acting amylin analog under development by OPKO Health. Amylin is co-secreted with insulin and regulates post-meal glucose by slowing gastric emptying, suppressing glucagon, and promoting satiety. Eloralintide is designed for once-weekly dosing, differentiating it from the short-acting pramlintide (Symlin). It is being studied for obesity and type 2 diabetes as a complement to GLP-1 based therapies.
Half-Life
Extended (lipid depot in stratum corneum)
~7 days (estimated, long-acting design)
Admin Route
Topical
SubQ
Research
Typical Dose
0.005–0.1% in formulation
Under investigation in Phase 1/2 trials
Frequency
Once or twice daily
Once weekly
Key Benefits
  • Stimulates collagen I and III synthesis in dermis
  • Reduces the appearance of fine lines and wrinkles
  • Improves skin elasticity and firmness
  • Inhibits collagenase (MMP-1) to preserve existing collagen
  • Enhances wound healing and skin repair
  • Well-tolerated in anti-aging serums and creams
  • Once-weekly dosing (vs multiple daily injections for pramlintide)
  • Appetite suppression via central amylin receptor activation
  • Reduction in post-meal glucagon secretion
  • Complementary mechanism to GLP-1 agonists for combination therapy
  • Slows gastric emptying for prolonged satiety
  • Potential additive weight loss when combined with GLP-1 agents
Side Effects
  • Generally very well-tolerated
  • Rare skin irritation at very high concentrations
  • Possible formulation-dependent comedogenicity
  • Nausea
  • Vomiting
  • Decreased appetite
  • Injection site reactions
  • +1 more
Stacks With